- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04270175
Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
July 2, 2023 updated by: Weill Medical College of Cornell University
This study will test the hypothesis that in patients with previous daratumumab exposure, combination therapy of daratumumab, pomalidomide, and dexamethasone (DPd) will yield higher complete remission (CR) rates in relapsed/refractory amyloidosis than historical pomalidomide/dexamethasone treatment.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
21
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Kathleen P Research Nurse Coordinator, RN
- Phone Number: 646-962-6500
- Email: kap9111@med.cornell.edu
Study Locations
-
-
California
-
Palo Alto, California, United States, 94304
- Recruiting
- Stanford University
-
Contact:
- Michaela Liedtke, MD
- Email: Mliedtke@Stanford.edu
-
Principal Investigator:
- Michaela Liedtke, MD
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02118
- Recruiting
- Boston University Medical Center
-
Principal Investigator:
- Vaishali Sanchorawala, MD
-
Contact:
- Vaishali Sanchorawala, MD
- Email: Vaishali.Sanchorawala@bmc.org
-
-
New York
-
New York, New York, United States, 10065
- Recruiting
- Weill Cornell Medicine - Multiple Myeloma Center
-
Principal Investigator:
- Cara Rosenbaum, MD
-
Contact:
- Research Nurse Coordinator
- Phone Number: 646-962-6500
- Email: kap9111@med.cornell.edu
-
Contact:
- Research Nurse Coordinator
- Phone Number: (646) 962-6500
- Email: naa9101@med.cornell.edu
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Recruiting
- Medical College of Wisconsin
-
Principal Investigator:
- Anita D'Souza, MD
-
Contact:
- Anita D'Souza, MD
- Email: anitadsouza@mcw.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Diagnosis of primary AL amyloidosis of tissue
- Relapsed and/or refractory AL amyloidosis
- Has received daratumumab or Faspro in any prior line of therapy
- Prior pomalidomide exposure allowed if ≥ PR achieved and no disease progression occurred within 60 days of last dose received
- Measurable disease
- Able to give voluntary written consent
- Eastern Cooperative Oncology Group performance status and/or other performance status 0, 1, or 2.
- Absolute neutrophil count (ANC) ≥ 1,000/mm3 and platelet count ≥ 75,000/mm3.
- Total bilirubin ≤ 1.5 × the upper limit of the normal range (ULN) (Total bilirubin ≥ 1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%)
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN.
- eGFR ≥ 20 mL/min/1.73 m2 (as calculated by Modified Diet in Renal Disease (MDRD) formula)
Exclusion Criteria:
- Non-AL amyloidosis
- Clinically overt myeloma
- Prior exposure to non-daratumumab anti-CD38 monoclonal antibodies.
- Clinically significant cardiac disease
- Severe obstructive airway disease
- Female patients who are lactating or have a positive serum pregnancy test during the screening period
- Planned high-dose chemotherapy and autologous stem cell transplantation within 6, 28-day treatment cycles after starting on treatment.
- Failure to have fully recovered (ie, ≤ Grade 1 toxicity) from the reversible effects of prior chemotherapy.
- Major surgery within 14 days before enrollment.
- Radiotherapy within 14 days before enrollment.
- Infection requiring systemic intravenous antibiotic therapy or other serious infection within 14 days before study enrollment. Systemic treatment, within 14 days before the first dose, with strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital, see Appendix 11.7), or use of Ginkgo biloba or St. John's wort.
- Positive for human immunodeficiency virus (HIV), hepatitis B, and hepatitis C
- Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: daratumumab/pomalidomide/dexamethasone
Pomalidomide: (4mg orally) on days 1-21 of a 28-day cycle Dexamethasone:
Daratumumab:
|
Given as 4mg oral capsule
Given as 1800mg via injection
Other Names:
Given as 20mg or 40 mg IV and 20mg or 40mg oral tablet.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Overall Complete Hematologic Response
Time Frame: Follow-up for up to 1 year
|
Overall complete hematologic response rate will be defined as percentage of participants who achieve Complete Hematologic Response
|
Follow-up for up to 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of Very Good Partial Response (VGPR) or better hematologic response rates
Time Frame: Follow-up for up to 5 years
|
Duration of hematologic VGPR or better response is defined as the time between the date of initial documentation of hematologic VGPR or better response to the date of first documented evidence of hematologic progressive disease.
|
Follow-up for up to 5 years
|
Low-dFLC Partial Response Rate (applicable to low-dFLC pt group)
Time Frame: Follow-up for up to 1 year
|
Percentage of participants who achieve a low-dFLC partial hematologic response rate and met criteria at screening for low-dFLC response assessment
|
Follow-up for up to 1 year
|
Percentage of participants with an Organ Response
Time Frame: Follow-up for up to 3 years
|
Organ response rate (OrRR) for kidney and cardiac is defined as the proportion of baseline organ involved participants who achieve organ response in each corresponding organ.
Organ response defined for cardiac: N-terminal brain pronatriuretic peptide (NT-proBNP) response (> 30% and > 300 nanogram per liter [ng/L] decrease in participants with baseline NT-proBNP >= 650 ng/L) or New York Heart Association (NYHA) class response (>= 2 class decrease in participants with baseline NYHA class 3 or 4); for kidney: decrease in proteinuria by >=30% or below 0.5 grams /24 hours without renal progression.
|
Follow-up for up to 3 years
|
Median estimate of months that participants have Progression Free Survival
Time Frame: Follow-up for up to 5 years
|
Median estimate calculated using the Kaplan-Meier methodology
|
Follow-up for up to 5 years
|
Median number of months of participant's Overall Survival
Time Frame: Follow-up for up to 5 years
|
Overall survival (OS) is measured from the date of enrollment to the date of the participant's death
|
Follow-up for up to 5 years
|
Time to Complete Hematologic Response
Time Frame: Follow-up for up to 1 year
|
Measured in months between the date of enrollment and the first efficacy evaluation at which the participant has met the criteria for hematologic complete response.
|
Follow-up for up to 1 year
|
Time to Hematologic Progression
Time Frame: Follow-up for up to 5 years
|
Measured in months between the date of enrollment and the first efficacy evaluation at which the participant has met the criteria for hematologic progression
|
Follow-up for up to 5 years
|
Time until Next Treatment Therapy
Time Frame: Follow-up for up to 5 years
|
Measured in months from the date of enrollment to the start date of subsequent treatment for AL amyloidosis
|
Follow-up for up to 5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Cara Rosenbaum, MD, Weill Medical College of Cornell University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 14, 2021
Primary Completion (Estimated)
December 1, 2024
Study Completion (Estimated)
December 1, 2028
Study Registration Dates
First Submitted
February 12, 2020
First Submitted That Met QC Criteria
February 12, 2020
First Posted (Actual)
February 17, 2020
Study Record Updates
Last Update Posted (Actual)
July 6, 2023
Last Update Submitted That Met QC Criteria
July 2, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Paraproteinemias
- Proteostasis Deficiencies
- Neoplasms, Plasma Cell
- Immunoglobulin Light-chain Amyloidosis
- Amyloidosis
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Immunologic Factors
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Dexamethasone
- Pomalidomide
- Daratumumab
Other Study ID Numbers
- 19-12021159
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on AL Amyloidosis
-
Nexcella Inc.Not yet recruitingLight Chain (AL) AmyloidosisUnited States
-
Peking Union Medical College HospitalRecruitingLight Chain (AL) Amyloidosis | Venetoclax | CCND1 TranslocationChina
-
Sorrento Therapeutics, Inc.WithdrawnLight Chain (AL) Amyloidosis
-
Boston Medical CenterMillennium Pharmaceuticals, Inc.Completed
-
European Myeloma NetworkJanssen PharmaceuticaActive, not recruitingLight Chain (AL) Amyloidosis, Stage 3BNetherlands, Greece, France, Italy
-
Tufts Medical CenterSanofiWithdrawnAmyloidosis | Light Chain (AL) Amyloidosis
-
Sorrento Therapeutics, Inc.RecruitingLight Chain (AL) AmyloidosisUnited States
-
IRCCS Policlinico S. MatteoTerminatedCardiac AL AmyloidosisSpain, France, Italy, Germany, Canada, Greece, Turkey, United Kingdom
-
Nanjing University School of MedicineRecruiting
-
Florian MichelGerman Federal Ministry of Education and ResearchCompletedLight Chain (AL) Amyloidosis | Cardiac InvolvementGermany
Clinical Trials on Pomalidomide
-
Kirby InstituteActive, not recruitingHigh Grade Squamous Intra-epithelial Lesion (HSIL)Australia
-
Amsterdam UMC, location VUmcNot yet recruitingMultiple Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory
-
Multiple Myeloma Research ConsortiumEli Lilly and Company; GlaxoSmithKline; AbbVie; Takeda; Genentech, Inc.; Celgene Corporation and other collaboratorsRecruitingRelapsed Refractory Multiple MyelomaUnited States
-
CelgeneTerminatedSystemic Sclerosis | Scleroderma, Systemic | Systemic Scleroderma | Interstitial Lung Disease | Sclerosis, SystemicUnited States, Spain, France, Australia, Italy, Switzerland, Germany, Poland, United Kingdom, Russian Federation
-
Stanford UniversityCelgene CorporationWithdrawnPulmonary FibrosisUnited States
-
CelgeneCompletedMultiple MyelomaCanada, Denmark, Australia, Belgium, France, Germany, Italy, Netherlands, Russian Federation, Spain, Sweden, Switzerland, United Kingdom, Czechia, Greece
-
CelgeneCompletedMultiple MyelomaBelgium, United Kingdom, Italy, Germany, Sweden, Denmark, Norway, Spain
-
Jiangsu Simcere Pharmaceutical Co., Ltd.Second Hospital of Shanxi Medical UniversityCompleted